Skip to main content
OpenTrials
Completed

NCT Number: NCT04745299

Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS

ALSUMMIT is a double-blind, randomized, placebo-controlled, multi-center, parallel, phase III clinical trial to evaluate and confirm the efficacy and long-term safety of repeated Lenzumestrocel (Neuronata-R® inj.) treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Amyotrophic Lateral Sclerosis Central Nervous System Diseases Metabolic Diseases Motor Neuron Disease Nervous System Diseases Neurodegenerative Diseases Neuromuscular Diseases Nutritional and Metabolic Diseases Proteostasis Deficiencies Spinal Cord Diseases TDP-43 Proteinopathies

Age range

25 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Pusan National University Yangsan Hospital, Yangsan, Kyungsangnam-do, South Korea

Loading trial locations.

About this study

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by selective and progressive loss of motor neurons. Disease progression leads to death within 2-4 years, but there exists no definite treatment so far.

Based on phase I/II clinical trial(NCT01363401), twice intrathecal autologous bone marrow-derived mesenchymal stem cells (Lenzumestrocel) injections showed significant therapeutic benefit lasting at least six months with safety in patients with ALS.

Additionally, the switch from pro- to anti-inflammatory conditions, which was indicated from the inverse correlation between TGF-β1 and MCP-1 levels after Lenzumestrocel injections in the good responder, has been considered a plausible beneficial action mechanism.

This study is designed to investigate the following. First, to reconfirm and evaluate the long-term efficacy of twice injections (single cycle) of Lenzumestrocel, group 1 will receive a single cycle injection with a 26-day interval.

Second, to evaluate the long-term safety and efficacy of Lenzumestrocel repeated injections, group 2 will receive a single cycle injection a 26-day apart followed by three times injections every three-month interval.

Group 3 will receive comparator injections.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

[Inclusion Criteria]

  • Subjects who show both upper motor neuron signs and lower motor neuron signs at the same time in neurological tests.
  • Among subjects diagnosed with familial or sporadic ALS, subjects falling into clinically definite ALS, probable ALS and probable ALS-lab supported according to The revised World Federation of Neurology El Escorial Criteria[Rix Brooks, 2000], during 17-weeks period prior to the administration and ALSFRS-R score (progression rate) of 1.03 ± 50%/month (meaning mean value in that total period).
  • For subjects who are under Riluzole treatment, those who have received stable dose of Riluzole for more than 28 days before screening visit.
  • Subjects with duration of disease of no more than 2 years from the first diagnosis date.
  • Subjects whose ALSFRS-R scores are in the range of 31~46 at the time of screening (P-V0).

[Exclusion Criteria]

  • Subjects who received tracheostomy or use ventilators (including positive pressure ventilators; subjects who use non-invasive ventilation for sleep apnea may be allowed after review) at the time of screening (P-V0).
  • Subjects who received gastrotomy at the time of screening (P-V0).
  • Subjects for whom clinical efficacy evaluation is not possible because pulmonary functional tests cannot be conducted at the time of screening (P-V0) or subjects whose forced vital capacity is found to be not greater than 40%of the expected value.
  • Subjects who fall into above Class II according to the New York Heart Association's functional classification, who have showed myocardial infarction, unstable arrhythmia and/or other significant cardiovascular diseases such as unstable angina in the past 3 months, or who show electrocardiographic signs of myocardial infarction or angina at the time of screening (P-V0) or who received stent insertion or coronary artery bypass grafting.
  • Subjects who have received other investigational products or edaravone within 3 month or 5 half-lives at the time of screening (P-V0) and lead in period visit L-V1 (evaluated by whichever is longer).
  • Subjects who have experienced epileptic seizure.
  • Subjects with severe renal disorder (serum creatinine: not less than 2.0 mg/dL).
  • Subjects with severe hepatic disorder (ALT, AST, or bilirubin: over 2.0 times of the normal upper limit).
  • Subjects who show hemorrhagic tendency at the time of screening (PT and aPTT > 1.5 x ULN)
  • Subjects who are found to have active viral infections (HBsAg, HCV Ab, HIV Ab, CMV IgM, EBV IgM, HSV IgM and Treponema pallidum) at the time of screening.
  • Subjects with hypersensitivity to antibiotics (penicillin or streptomycin).
  • Subjects who have ever received any cell therapy product for the same disease.
  • Subjects with any malignant tumor in the past 5 years before screening, except malignant tumors with very low risk of metastasis or death.

Treatment and study plan

Lenzumestrocel

Biological

Single cycle administration group : injections twice in a 26-day interval Multiple administration group : injections twice in a 26-day interval followed by repeated three times injections every three months

Other names: Neuronata-R inj, Autologous Bone Marrow derived Mesenchymal Stem Cell

Riluzole

Drug

concomitant administration of Riluzole to all groups, except subjects to whom Riluzole administration is deemed impossible owing to adverse events as determined by medical experts

Other names: Rilutek

placebo comparator

Drug

Single cycle administration group: Placebo comparator is injected three times every three months after injection of Lenzumestrocel twice in a 26-day interval.

Control group: Placebo comparator is injected twice in a 26-day interval followed by repeated three times injcections every three months

Other names: Normal Saline Inj.

Primary outcomes

  1. Joint rank scores (CAFS, Combined Assessment of Functional and Survival)

    Time frame: at 12 months, and 6 months

    Joint rank score is derived from Combined Assessment of Function and Survival. Functional assessment is based on ALSFRS-R scores and survival assessment is based on the period from randomization to physical death. Joint rank score will be calculated with ALSFRS-R score data and survival. For each pairwise comparison, a study participant is assigned a score and then the summed scores are ranked for all participants.

    The higher ranking, the higher score, and the lower ranking, the lower score. And the average rank score is then calculated for each treatment group. A higher mean rank score indicates that participants in that treatment group, on average, fared better.

    • The difference in joint rank scores between multiple administration group and control group at 12 months.
    • The difference in joint rank scores between single cycle administration group and control group at 6 months

Secondary outcomes

  1. Joint rank scores (CAFS, Combined Assessment of Functional and Survival)

    Time frame: at 6 months

    Joint rank score is derived from Combined Assessment of Function and Survival. Functional assessment is based on ALSFRS-R scores and survival assessment is based on the period from randomization to physical death. Joint rank score will be calculated with ALSFRS-R score data and survival. For each pairwise comparison, a study participant is assigned a score and then the summed scores are ranked for all participants.

    The higher ranking, the higher score, and the lower ranking, the lower score. And the average rank score is then calculated for each treatment group. A higher mean rank score indicates that participants in that treatment group, on average, fared better.

    The difference in joint rank scores between multiple administration group and control group at 6 months.

  2. Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score

    Time frame: at 12 months, 6 months

    ALSFRS-R is an instrument designed to evaluate functional status of subjects with amyotrophic lateral sclerosis (Lou Gehrig's disease), such as gross motor activity, fine motor activity, bulbar function and respiration function. It consists of 12 items; 3 items for mouth functions, 4 items for upper limb and overall fine motor functions, 2 items for lower limb functions and 3 items for respiration functions. Each item is evaluated in 5-point scale (0~4). A higher score means a better functional status.

    • Change of ALSFRS-R score measured at baseline and 12 months (multiple administration group and control group)
    • Change of ALSFRS-R score measured at baseline and 6 months (single cycle administration and control group)

  3. Time to event

    Time frame: at 12 months, 6 months

    Time to Event is defined as physical death, tracheostomy recognized as the point where disease progression functionally stops or chronic use of ventilator, whichever comes earlier. Chronic use of ventilator means that ventilator is used for more than 20 hours in a day and such use is continued for more than 30 days and that a subject in vegetative state requires full supports from other persons to maintain living.

    • Time to event for 12 months (multiple administration group and control group)
    • Time to event for 6 months (single cycle administration group and control group)

Other outcomes

  1. Slow Vital Capacity (SVC)

    Time frame: 6 months, 12 months, 36 months

    Change to SVC measured at 6, 12 months and 36 months

  2. Muscular strength

    Time frame: 6 months, 12 months, 36 months

    Change of Muscular strength which is measured by Hand Held Dynamometer (HHD)

  3. Time to event

    Time frame: 36 months

    Time to event for 36 months

  4. Time to death

    Time frame: 6 months, 12 months, 36 months

    Time to death means the period from randomization of a subject to physical death.

    The comparison with the time to death between treatment groups and control group.

  5. EuroQol Short Form (EQ-5D-5L)

    Time frame: 6 month, 12 months, 36 months

    EQ-5D-5L is designed to measure health conditions and it consists of 5 questions relating to mobility, self-care, usual activities, pain/discomfort and anxiety/depression. 1~5 points are given for each question and a higher score means worse condition.

    Change of EQ-5D-5L from baseline to 6 month, 12 months, and 36 months.

  6. Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40)

    Time frame: 6 month, 12 months, 36 months

    ALSAQ-40 is designed to evaluate disease-specific health conditions of subjects with ALS/motor neural disease. It consists of 40 questions to evaluate 5 aspects of health conditions affected by the disease. Subjects are asked to think about the difficulties they may have experienced during the last 2 weeks. Subjects are asked to indicate the frequency of each event by selecting one of 5 options (0~4): never/rarely/sometimes/often/always or cannot do at all.

  7. Biological test

    Time frame: up to 12 months after administration

    Tests on blood samples and cerebrospinal fluid samples for exploratory investigation of biological markers in plasma, blood and CSF.

    Comparison of change before and after treatment.

    • Measurement cytokines : TGF-β1, IL-10, IL-6, TNF-α, MCP-1, IL-8, IL-1RA, MIP-1β, RANTES and IP-10 etc.
    • Units of Measure: pg/mL
    • Comparative Analysis of how much each cytokine increases or decreases after treatment compared to before treatment.

Sponsors and collaborators

Lead sponsor

Corestemchemon, Inc.

Industry

Registry information

Official study title

A Double-blind, Randomized, Multicenter, Placebo-Controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Lenzumestrocel(Neuronata-R® Inj.) in Patients With Amyotrophic Lateral Sclerosis

Acronym: ALSummit

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Feb 9, 2021
Registry last updated
Apr 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.